• A. Renal failure
  • B. Liver toxicity ✓
  • C. Seizures
  • D. Congestive heart failure


Isoniazid (INH) is a medication commonly used to treat tuberculosis and isoniazid preventive therapy (IPT) is recommended for individuals with a positive purified protein derivative (PPD) test to prevent the development of active tuberculosis. However, treatment with isoniazid during pregnancy may be associated with liver toxicity in some cases. Pregnant women are at an increased risk of developing drug-induced liver injury due to physiological changes that occur during pregnancy, such as alterations in drug metabolism and increased susceptibility to hepatotoxicity.

The use of isoniazid in pregnant women should be carefully monitored by healthcare providers to assess liver function and detect any signs of liver toxicity early on. If liver toxicity is suspected, the medication may need to be discontinued, and alternative treatment options considered to ensure the safety of both the mother and the fetus.

In summary, treatment with isoniazid for a positive PPD conversion during pregnancy may be associated with liver toxicity, highlighting the importance of close monitoring and prompt intervention in pregnant women receiving this medication.

In other words, Isoniazid (INH) is a medication commonly used to treat tuberculosis. When given to pregnant women with a positive purified protein derivative (PPD) conversion, it may be associated with maternal liver toxicity. Liver toxicity is a known side effect of INH, and pregnancy can sometimes exacerbate the risk of adverse effects.

During pregnancy, the body undergoes various physiological changes that can affect how medications are metabolized. The liver plays a crucial role in drug metabolism, and certain medications, like INH, can put additional stress on the liver, potentially leading to liver toxicity.

Liver toxicity from INH can manifest as elevated liver enzymes in blood tests, jaundice (yellowing of the skin and eyes), abdominal pain, nausea, vomiting, and fatigue. Severe cases of liver toxicity can progress to acute liver failure, which is a life-threatening condition requiring immediate medical attention.

Therefore, when considering treatment with INH for a positive PPD conversion during pregnancy, healthcare providers need to weigh the potential benefits of treating tuberculosis against the risks of maternal liver toxicity. Close monitoring of liver function through regular blood tests is essential to detect any signs of liver damage early on and adjust the treatment plan accordingly.